Potential of fluorescent metalloproteinase substrates for cancer detection

Clinical Biochemistry

Volumn 44, Issue 17-18, 2011, Pages 1434-1439

  Roy, Roopali ^a   Zurakowski, David ^a   Pories, Susan ^b   Moses, Marsha A ^a   Moss, Marcia L ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BioZyme Inc   (United States)

Author keywords

ADAMs; Breast cancer; Enzyme activity; FRET substrates; Invasive; Metastatic; MMPs; Urine

Indexed keywords

ADAM 12; ADAM 8; ADAM PROTEIN; FLSUB13 PROTEIN; FLSUB21 PROTEIN; GELATINASE A; GELATINASE B; METALLOPROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; PILOT STUDY; PRIORITY JOURNAL; SCREENING TEST; URINALYSIS;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CASE-CONTROL STUDIES; ENZYME ASSAYS; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT DYES; HUMANS; LOGISTIC MODELS; METALLOENDOPEPTIDASES; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 81555219466     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.09.016     Document Type: Article

References (44)

1. Roy R., Zhang B., Moses M.A. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 2006, 312:608-622.
2. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997, 89:1260-1270.
3. Kleiner D.E., Stetler-Stevenson W.G. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999, 43:S42-S51. Suppl.
4. Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999, 189:300-308.
5. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
6. Fang J., Shing Y., Wiederschain D., Yan L., Butterfield C., Jackson G., Harper J., Tamvakopoulos G., Moses M.A. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000, 97:3884-3889.
7. Bergers G., Javaherian K., Lo K.M., Folkman J., Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999, 284:808-812.
8. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
9. Bode W. Structural basis of matrix metalloproteinase function. Biochem Soc Symp 2003, 1-14.
10. Seals D.F., Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003, 17:7-30.
11. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol Aspects Med 2008, 29:258-289.
12. Maretzky T., Schulte M., Ludwig A., Rose-John S., Blobel C., Hartmann D., Altevogt P., Saftig P., Reiss K. L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol 2005, 25:9040-9053.
13. Khokha R., Werb Z. Mammary gland reprogramming: metalloproteinases couple form with function. Cold Spring Harb Perspect Biol 3 2010.
14. Cawston T.E., Wilson A.J. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 2006, 20:983-1002.
15. Turner S.L., Blair-Zajdel M.E., Bunning R.A. ADAMs and ADAMTSs in cancer. Br J Biomed Sci 2009, 66:117-128.
16. Moali C., Hulmes D.J. Extracellular and cell surface proteases in wound healing: new players are still emerging. Eur J Dermatol 2009, 19:552-564.
17. Aiken A., Khokha R. Unraveling metalloproteinase function in skeletal biology and disease using genetically altered mice. Biochim Biophys Acta 2010, 1803:121-132.
18. Pories S.E., Zurakowski D., Roy R., Lamb C.C., Raza S., Exarhopoulos A., Scheib R.G., Schumer S., Lenahan C., Borges V., Louis G.W., Anand A., Isakovich N., Hirshfield-Bartek J., Wewer U., Lotz M.M., Moses M.A. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 2008, 17:1034-1042.
19. Smith E.R., Zurakowski D., Saad A., Scott R.M., Moses M.A. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008, 14:2378-2386.
20. Roy R., Louis G., Loughlin K.R., Wiederschain D., Kilroy S.M., Lamb C.C., Zurakowski D., Moses M.A. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008, 14:6610-6617.
21. Chan L.W., Moses M.A., Goley E., Sproull M., Muanza T., Coleman C.N., Figg W.D., Albert P.S., Menard C., Camphausen K. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 2004, 22:499-506.
22. Jung K., Krell H.W., Ortel B., Hasan T., Romer A., Schnorr D., Loening S.A., Lein M. Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats. Prostate 2003, 54:206-211.
23. Davies B., Waxman J., Wasan H., Abel P., Williams G., Krausz T., Neal D., Thomas D., Hanby A., Balkwill F. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993, 53:5365-5369.
24. Wu Z.S., Wu Q., Yang J.H., Wang H.Q., Ding X.D., Yang F., Xu X.C. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008, 122:2050-2056.
25. Vasala K., Paakko P., Turpeenniemi-Hujanen T. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis. Anticancer Res 2008, 28:1757-1761.
26. Fernandez C.A., Yan L., Louis G., Yang J., Kutok J.L., Moses M.A. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005, 11:5390-5395.
27. Moses M.A., Wiederschain D., Loughlin K.R., Zurakowski D., Lamb C.C., Freeman M.R. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998, 58:1395-1399.
28. Yan L., Borregaard N., Kjeldsen L., Moses M.A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001, 276:37258-37265.
29. Smith E.R., Manfredi M., Scott R.M., Black P.M., Moses M.A. A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery 2007, 60:E1148-E1149. discussion E1149.
30. La Rocca G., Pucci-Minafra I., Marrazzo A., Taormina P., Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004, 90:1414-1421.
31. Roy R., Wewer U.M., Zurakowski D., Pories S.E., Moses M.A. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004, 279:51323-51330.
32. Frohlich C., Albrechtsen R., Dyrskjot L., Rudkjaer L., Orntoft T.F., Wewer U.M. Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res 2006, 12:7359-7368.
33. Beekman B., van El B., Drijfhout J.W., Ronday H.K., TeKoppele J.M. Highly increased levels of active stromelysin in rheumatoid synovial fluid determined by a selective fluorogenic assay. FEBS Lett 1997, 418:305-309.
34. Rasmussen F.H., Yeung N., Kiefer L., Murphy G., Lopez-Otin C., Vitek M.P., Moss M.L. Use of a multiple-enzyme/multiple-reagent assay system to quantify activity levels in samples containing mixtures of matrix metalloproteinases. Biochemistry 2004, 43:2987-2995.
35. Moss M.L., Rasmussen F.H. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal Biochem 2007, 366:144-148.
36. Moss M.L., Sklair-Tavron L., Nudelman R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 2008, 4:300-309.
37. Altman D. Practical statistics for medical research 1991, Chapman & Hall, New York.
38. Katz M. Multivariable analysis: a practical guide for clinicians 2006, Cambridge University Press, New York.
39. Harrell F. Regression modeling strategies. With applications to linear models, logistic regression, and survival analysis 2001, Springer, New York.
40. Pepe M. The statistical evaluation of medical tests for classification and prediction 2004, Oxford University Press, New York.
41. Stokes A., Joutsa J., Ala-Aho R., Pitchers M., Pennington C.J., Martin C., Premachandra D.J., Okada Y., Peltonen J., Grenman R., James H.A., Edwards D.R., Kahari V.M. Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res 2010, 16:2022-2035.
42. Moss M.L., Rasmussen F.H., Nudelman R., Dempsey P.J., Williams J. Fluorescent substrates useful as high-throughput screening tools for ADAM9. Comb Chem High Throughput Screen 2010, 13:358-365.
43. Lambert M.H., Blackburn R.K., Seaton T.D., Kassel D.B., Kinder D.S., Leesnitzer M.A., Bickett D.M., Warner J.R., Andersen M.W., Badiang J.G., Cowan D.J., Gaul M.D., Petrov K.G., Rabinowitz M.H., Wiethe R.W., Becherer J.D., McDougald D.L., Musso D.L., Andrews R.C., Moss M.L. Substrate specificity and novel selective inhibitors of TNF-alpha converting enzyme (TACE) from two-dimensional substrate mapping. Comb Chem High Throughput Screen 2005, 8:327-339.
44. Miller M.A., Barkal L., Jeng K., Herrlich A., Moss M., Griffith L.G., Lauffenburger D.A. Proteolytic activity matrix analysis (PrAMA) for simultaneous determination of multiple protease activities. Integr Biol (Camb). 2010, 4:422-438.